Skip to main content Accessibility help

Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts

  • Nathan Herrmann (a1), Sandra E. Black (a2), Abby Li (a3) and Krista L. Lanctôt (a4)


Background: Cholinesterase inhibitors (ChEIs) are being used for increasingly long periods of time, even in patients with severe Alzheimer's disease. Because there is little data to help clinicians to decide on when it is safe and appropriate to discontinue ChEIs after long-term use, practices may vary widely.

Methods: An internet-based survey was undertaken of Canadian dementia experts (geriatric psychiatrists, neurologists, geriatricians) involved in clinical trial research. Recommendations for ChEI discontinuation were determined based on responses to questions dealing with patient/caregiver preference, administrative considerations, effectiveness, and adverse events.

Results: There was reasonable consensus that ChEIs should be discontinued based on patient and caregiver preference, and in the presence of severe bothersome adverse events. There was much less consensus on issues related to effectiveness – in particular, what constitutes greater than expected decline. There was a general reluctance to rely on any single measure of cognition, function and/or behavior, and in particular, the MMSE was seen as unhelpful for making decisions about discontinuation.

Conclusion: Recommendations for discontinuing ChEIs after long-term use from a survey of dementia experts are presented. Ideally, clinical practice guidelines based on controlled discontinuation trials are needed.


Corresponding author

Correspondence should be addressed to: Dr. Nathan Herrmann, Department of Psychiatry, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada. Phone: +1 416-480-6133; Fax: +1 416-480-6022. Email:


Hide All
American Psychiatric Association (2007). Practice guidelines for the treatment of patients with Alzheimer's disease and other dementias. Second Edition. American Journal of Psychiatry, 164, 156.
Ballard, C. G. et al. (2004). A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. Journal of Clinical Psychiatry, 65, 114119.
Behl, P., Lanctôt, K. L., Streiner, D. L. and Black, S. E. (2008). The effect of cholinesterase inhibitors on decline in multiple functional domains in Alzheimer's disease: a two-year observational study in the Sunnybrook dementia cohort. International Psychogeriatrics, 20, 11411159.
Bullock, R. and Dengiz, A. (2005). Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. International Journal of Clinical Practice, 59, 817822.
Burns, A., Gauthier, S. and Perdomo, C. (2007). Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry, 22, 806812.
Daiello, L. A., Ott, B. R., Lapane, K. L., Reinert, S. E., Machan, J. T. and Dore, D. D. (2009). Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. American Journal of Geriatric Pharmacotherapy, 7, 7483.
Gill, S. S. et al. (2009). Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Archives of Internal Medicine, 169, 867873.
Herrmann, N. (2007). Treatment of moderate to severe Alzheimer's disease: rationale and trial designs. Canadian Journal of Neurological Sciences, 34, 103108.
Herrmann, N., Gauthier, S. and Lysy, P. (2007a). Clinical practice guidelines for severe Alzheimer's disease. Alzheimer's and Dementia, 3, 385397.
Herrmann, N. et al. (2007b). A population-based study of cholinesterase inhibitor use for dementia. Journal of the American Geriatrics Society, 55, 15171523.
Hogan, D. B. et al. (2007). Management of mild to moderate Alzheimer's disease and dementia. Alzheimer's and Dementia, 3, 355384.
Holmes, C. et al. (2004). The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology, 63, 214219.
Jones, R. et al. (2009). DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. Trials, 10, 57.
Kaduszkiewicz, H., Zimmermann, T., Beck-Bornholdt, H. P. and van den Bussche, H. (2005). Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ, 331, 321327.
Lanctôt, K. L. et al. (2003). Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. Canadian Medical Association Journal, 169, 557564.
Lanctôt, K. L., Rajaram, R. and Herrmann, N. (2009). Therapy for Alzheimer's disease: how effective are current treatments? Therapeutic Advances in Neurological Disorders, 2, 163180.
Lee, J., Monette, J., Sourial, N., Monette, M. and Bergman, H. (2007). The use of a cholinesterase inhibitor review committee in long-term care. Journal of the American Medical Directors Association, 8, 243247.
Raskind, M. A., Peskind, E. R., Truyen, L., Kershaw, P. and Damaraju, C. V. (2004). The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Archives of Neurology, 61, 252256.
Ruths, S., Straand, J., Nygaard, H. A., Bjorvatn, B. and Pallesen, S. (2004). Effect of antipsychotic withdrawal on behavior and sleep/wake activity in nursing home residents with dementia: a randomized, placebo-controlled, double-blinded study. The Bergen District Nursing Home Study. Journal of the American Geriatrics Society, 52, 17371743.
Seltzer, B. (2007). Is long-term treatment of Alzheimer's disease with cholinesterase inhibitor therapy justified? Drugs and Aging, 24, 881890.
Simpson, S., Beavis, D., Leddy, A. and Ball, S. (2005). Naturalistic audit of NICE criteria for the use of cholinesterase inhibitors. Psychiatric Bulletin, 29, 410412.
Singh, S. and Dudley, C. (2003). Discontinuation syndrome following donepezil cessation. International Journal of Geriatric Psychiatry, 18, 282284.
Vellas, B. et al. (2005). Consensus statement on dementia of Alzheimer type in the severe stage. Journal of Nutrition, Health and Aging, 9, 330338.



Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed